Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleVenture capital is pouring into women's health on the promise of a trillion-dollar productivity gap, but endometriosis still takes years to diagnose and most osteoporotic fracture patients never get treated. Both conditions have had effective treatments for decades. The bottleneck was never the molecule; it was the last mile between diagnosis and care.
UPM and Sappi want to merge their European graphic paper businesses to manage a market that has shrunk by double digits for years. The European Commission's objection rests on the same fact the merger does: in a dying industry, consolidation is both the rational response to decline and the riskiest thing left for the customers who still need the product.
Sword Health, an AI-guided physical therapy company with no consumer brand, is acquiring Headspace, the meditation app that defined digital mental health in the 2010s. The deal is the clearest evidence yet that in health care, the durable moat migrated from brand and users to the enterprise contract.
An Oxford study using the 2017 Shingrix approval date as a natural experiment found 9 percent less cardiovascular disease in recipients versus the older shingles vaccine. The design elegantly removes the usual healthy-vaccinee bias, but it is still an observational study, and a randomized Danish trial of 162,000 people will settle the question in 2027.
American family caregivers provide roughly $1.01 trillion a year of unpaid labor, more than total Medicaid spending. The system captures the savings in budgets and premiums; the sandwich generation, mostly women in their peak earning years, captures none of it, and pays for it in wages, savings, and retirement.
New York's new medical aid in dying law is the strictest in the country, requiring a recorded oral request, two physicians, a mandatory mental health evaluation, and a five-day wait. Every safeguard answers a real objection, but the process runs on specialists the state's own workforce data says are scarce, and the friction quietly sorts who can complete it.
Two unvaccinated people died of measles in Lancaster County, Pennsylvania, the state's first measles deaths in over three decades. The outbreak traces to a gap in the herd-immunity shield that worked so quietly for a quarter century that a large share of the public stopped believing the danger behind it was real.
New cardiology guidelines now call for testing every adult once for lipoprotein(a), a genetic cholesterol particle absent from the standard lipid panel, even though no approved drug yet lowers it. The measurement is running ahead of the medicine on a deliberate bet that treatment is a year away.
Both sides of the abortion debate made confident predictions after Dobbs. Four years of studies later, one prediction held, one reversed, and two dissolved into competing research reading the same numbers in opposite directions. The failure of the scoreboard says more about how policy meets data than about which side was right.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareGartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse ResearchWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.